Researchers at the University of California, San Francisco have published findings indicating that psilocybin, a classic psychedelic compound, may possess anti-inflammatory properties in humans. The study, appearing in JAMA Psychiatry, analyzed blood samples from participants with Parkinson’s disease before and after psilocybin treatment sessions, measuring inflammatory signaling molecules and mitochondrial stress markers.
Participants demonstrated significantly reduced inflammation levels following two psilocybin sessions, with these improvements persisting approximately one month after the final dose. Blood markers indicating mitochondrial stress also showed substantial improvement immediately following treatment, though longer-term benefits in this measure were less pronounced. The research built upon a pilot safety study conducted the previous year that had assessed the feasibility of administering psilocybin to individuals with neurodegenerative disease, a population typically excluded from psychedelic trials due to safety considerations.
Dr. Ellen Bradley, an associate professor of psychiatry at UCSF, emphasized that the findings provide preliminary biological evidence for further investigation, though the study contained limitations including lack of a control group and participant awareness of receiving the active drug. Co-author Aoife O’Donovan noted that the objective markers observed over time provide confidence to pursue additional research in this area.
Experts outside the study, including researchers who conducted foundational work on psychedelics’ anti-inflammatory mechanisms fifteen years ago, characterized the findings as significant validation of prior laboratory and animal model research. The results suggest potential applications extending beyond Parkinson’s disease to other conditions involving inflammation and immune dysregulation, including neuropsychiatric and cardio-metabolic disorders. However, researchers cautioned that findings require confirmation through subsequent controlled studies before definitive claims can be made regarding therapeutic applications.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI